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Abstract  32 
Background/Aims: Knock-down of protein tyrosine phosphatase non-receptor type 2 (PTPN2), 33 
exaggerates IFN-y-induced intestinal barrier defects, but mice constitutively lacking PTPN2 in 34 
epithelial cells (PTPN2xVilCre mice) do not show changes in epithelial function or enhanced 35 
susceptibility to experimental colitis. Here, we investigated whether PTPN2 modulates the expression 36 
of related tyrosine phosphatases.  37 
 38 
Methods: PTPN2 knock-down in HT-29 cells was induced using siRNA constructs. Acute colitis in 39 
PTPN2xVilCre mice was induced by 2% DSS in drinking water for 7 days. Colitis-associated tumours 40 
were induced by injection of azoxymethane prior to treatment with DSS for 3 consecutive cycles. 41 
 42 
Results: In HT-29 cells, PTPN2-depletion resulted in enhanced mRNA expression of PTPN11 and 43 
PTPN23 and in parallel to upregulation of IL18 mRNA upon treatment with TNF for 24h. DSS 44 
treatment of PTPN2-deficient mice resulted in a strong induction of Ptpn23 mRNA in in colon tissue in 45 
vivo. In the tumour model, Ptpn23 mRNA was again clearly upregulated in non-tumour tissue from 46 
PTPN2-deficient mice, however, this was not observed in tumour tissue. 47 
 48 
Conclusions: Our experiments show that PTPN23 function might, at least partially, compensate lack 49 
of PTPN2 in epithelial cells. Up-regulation of PTPN23 might therefore crucially contribute to the lack of 50 
a colitis phenotype in PTPN2-VilCre mice. 51 
 52 
Key words: tyrosine phosphatases, HD-PTP; TC-PTP; intestinal inflammation; intestinal epithelial 53 
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1. Introduction 56 
Inflammatory bowel disease (IBD) is characterized by a chronic, relapsing and remitting inflammation 57 
of the gastrointestinal tract. Patients suffer from abdominal pain, diarrhea, and extra-intestinal 58 
manifestations, including skin rashes, uveitis, and arthritis are common complications. Further, 59 
patients with longstanding disease course might be at a higher risk of developing both, gastrointestinal 60 
as well as extra-intestinal malignancies, including skin cancer, lymphoma, and colorectal cancer 61 
(CRC) [1]. The increased risk to develop CRC is primarily due to the fact that chronic inflammation and 62 
recurrent epithelial defects might promote aberrant proliferation and malignant transformation of 63 
intestinal epithelial cells [2].  64 
 65 
Although the exact etiopathogenesis of IBD has not been completely understood, it is commonly 66 
accepted that genetic, immunological, environmental and bacterial factors play a key role in the 67 
development of chronic intestinal inflammation [3]. Genome-wide association studies (GWAS) 68 
identified 240 genetic loci that affect the susceptibility to develop IBD, including protein tyrosine 69 
phosphatase non-receptor type 2 (PTPN2, also referred to as T cell protein tyrosine phosphatase (TC-70 
PTP)) [4-6]. Variants in the gene locus encoding PTPN2 are associated with both, CD and UC [7]. 71 
PTPN2 is a member of the protein tyrosine phosphatase (PTPs) family, which, together with protein 72 
tyrosine kinases (PTKs), are responsible for regulating the phosphorylation status of intracellular 73 
proteins [8]. Phosphorylation and de-phosphorylation of protein tyrosine residues are essential 74 
mechanisms for activating or de-activating intracellular signaling cascades.  75 
 76 
PTPN2 is expressed in all tissues of the body, and in humans two splicing variants with slightly 77 
different subcellular localization patterns have been documented [9]. Since PTPN2 exerts obviously 78 
important anti-inflammatory functions, genetic deletion of PTPN2 in mice leads to death not later than 79 
5 weeks after birth as a result of systemic inflammation with signs of severe colitis [10]. 80 
 81 
Intestinal epithelial cells (IECs) form a tight intestinal epithelial barrier to prevent food particles and 82 
intestinal bacteria from unlimited access to the host [11]. In IBD patients, defects in the epithelial 83 
barrier and increased intestinal permeability have been well documented [12,13]. An important 84 





mRNA and protein expression, and PTPN2 in turn negatively regulates IFN-y induced signaling 86 
cascades and dampens IFN-y-induced barrier defects [15]. Elevated PTPN2 mRNA and protein levels 87 
are found in colonic tissue samples of CD patients with acute inflammation, but not in samples of CD 88 
patients in remission [16]. PTPN2 knockdown in cell culture experiments exaggerates IFN-y-induced 89 
epithelial barrier permeability, and promotes pro-inflammatory cytokine secretion [15]. These in vitro 90 
findings suggest that PTPN2 is important for the preservation of intestinal barrier functions, especially 91 
upon inflammatory insults. However, in vivo experiments from Kasper et al. showed that mice that 92 
specifically lack PTPN2 in IECs do not show enhanced disease severity upon induction of acute or 93 
chronic dextran sodium sulfate (DSS)-mediated colitis. Of note, those mice exhibit increased IEC 94 
proliferation and faster intestinal wound healing [17]. 95 
 96 
These rather unexpected findings led us to the hypothesis that in mice lacking PTPN2 in the intestinal 97 
epithelium, upregulated expression of other tyrosine phosphatases might compensate for the loss of 98 
PTPN2. Therefore, the aim of the here presented work was to investigate whether loss of PTPN2 in 99 
IECs results in up-regulation of non-receptor protein tyrosine phosphatases that de-phosphorylate 100 






2. Material and Methods 103 
2.1. Cell culture and siRNA transfections 104 
HT-29 cells were obtained from DSMZ (Braunschweig, Germany) and cultured as described 105 
previously [17] in culture medium (DMEM; Thermo Fisher Scientific, Waltham, MA), supplemented 106 
with 1% non-essential amino acids (Thermo Fisher Scientific) and 10% FCS. For experiments, 1 x 106 107 
cells were seeded in 12-well plates. For siRNA transfections, medium was changed to serum free 108 
DMEM, and 50pmol of three different PTPN2-specific siRNA constructs, or 50 pmol of three different 109 
non-targeting control siRNA constructs were mixed with RNAiMAX transfection reagent (Thermo 110 
Fisher Scientific) and applied to the cells. After 12h the medium was changed for normal culture 111 
medium. 24 h after the transfection, cells were treated with 100g/ml IFN-y, or 100g/ml TNF and 112 
RNA was harvested 24h later. 113 
2.2. Mice 114 
C57/Bl6 mice with a floxed PTPN2 gene (PTPN2fl/fl mice, termed wild-type throughout the 115 
manuscript) and PTPN2fl/fl mice expressing Cre-recombinase under the Villin promoter 116 
(PTPN2xVilCre mice) that lack PTPN2 specifically in intestinal epithelial cells [17] were used for all 117 
studies. Acute colitis was induced via administration of 2.5% DSS in the drinking water as described 118 
by Kasper et al. [17]. To induce colitis-associated tumours, mice were treated for 3 consecutive cycles 119 
consisting of 7 days with 1.5% DSS followed by 10 days recovery phase, each. At the first day of each 120 
cycle, mice were injected with 10mg/kg body weight azoxymethane (AOM). All animal experiments 121 
were performed according to local animal welfare legislation and were approved by the Veterinary 122 
Office of the Canton Zurich (ZH-255/2014). 123 
 124 
2.3. RNA Isolation 125 
Tissue samples were frozen in liquid nitrogen and stored in -80°C until RNA isolation. Cells were 126 
washed two times in ice cold PBS, lysed in 350 μl RLT buffer and homogenized using a 26G needle. 127 
Colon pieces were mechanically disrupted in 350 μl RLT buffer and Dithiothreitol (Qiagen, Düsseldorf, 128 





isolate total RNA, the RNeasy Plus Mini Kit (Qiagen) was used according to the manufacturer’s 130 
instructions. RNA concentration was measured with a spectrophotometer NanoDrop ND1000 131 
(NanoDrop Technologies, Wilmington, USA) by absorbance at 260 nm.  132 
2.4. Reverse transcription and real-time polymerase chain reaction (RT-PCR) 133 
A total of 1ug RNA was transcribed to complementary DNA (cDNA) using the High-Capacity cDNA 134 
Reverse Transcription Kit (Thermo Fisher Scientific, 4368813). Real-time polymerase chain reaction 135 
(PCR) was performed using FAST qPCR MasterMix for Taqman Assays (Thermo Fisher Scientific) on 136 
a Fast HT7900 Real-Time PCR system using SDS Software (Thermo Fisher Scientific) with the 137 
following amplification steps: Initial enzyme activation for 5 min at 95°C, followed by 45 cycles of 138 
denaturing for 15 sec at 95°C and annealing/extending for 1 min at 60°C, each. Measurements were 139 
performed in triplicates using mouse -actin as endogenous control. Results were analyzed using the 140 
CT method. 141 
2.5. Western blotting 142 
For Western blot analyses, cells were washed two times in PBS prior to lysis in M-PER buffer (Thermo 143 
Fisher Scientific) according to the manufacturer’s instructions. After 30 min. lysates were centrifuged 144 
for 10 min at 17’000 x g and protein-containing supernatants collected into fresh tubes. Aliquots 145 
containing equal amounts of protein were loaded on 10% polyacrylamide gels and proteins separated 146 
for 1 h prior to blotting onto nitrocellulose membranes. Membranes were blocked for 1 h at room 147 
temperature with 3% milk, 1% BSA in Tris-buffered saline containing 1% Tween (TBST) prior to 148 
incubation with anti-HD-PTP (1:100, Atlas antibodies, Stockholm, Sweden), anti PTPN2 (1:500, 149 
Millipore-Merck, Burlington, MA), anti-IL-18 (1:500; R&D Systems, Minneapolis, MN) or anti-b-actin 150 
(1:10’000; Millipore-Merck) antibodies over night. After washing three times in TBST, membranes 151 
were incubated with HRP-coupled secondary antibody (1:3’000; Santa Cruz Biotechnologies, Dallas, 152 






2.6. Enzyme-linked Immunosorbent Assay (ELISA) 155 
Anti-human and anti mouse IL-18 ELISA kits were purchased from R&D systems and 100 l cell 156 
culture supernatant or 50 l serum used for detection of IL-18 according to the manufacturer’s 157 
instructions. 158 
2.7. Immunhistochemistry (IHC) 159 
IHC was performed on formalin-fixed, paraffin-embedded tissue specimen using a peroxidase-based 160 
method with diaminobenzidine (DAB) chromogen. Tissue samples were incubated with Histoclear 161 
(Chemie-Brunschwig, Basel, Switzerland) and descending concentrations of ethanol. Antigen retrieval 162 
was performed using citrate buffer, pH 6.0 (DAKO, Glostrup, Denmark) for 30 min at 98 °C. 163 
Endogenous peroxidases were deleted by incubation with 0.9 % hydrogen peroxide for 15 min at room 164 
temperature (RT) and blocking was performed using 3 % bovine serum albumin (BSA) for 2 h. 165 
Sections were stained over night at 4°C with an anti-mouse PTPN23 antibody (Novus biologicals, 1:50 166 
dilution). HRP-labeled secondary anti-rabbit IgG-antibody (Vector laboratories, Peterborough, UK) was 167 
applied for 1 h at RT and antibody binding visualized by a Liquid DAB+ Substrate Chromogen System 168 
(Vector laboratories). Then samples were counterstained with hematoxylin, dehydrated in ascending 169 
concentrated ethanol and Histoclear solutions and finally mounted. Microscopic assessment was done 170 
using an AxioCam HRc (Zeiss, Jena, Germany) on a Zeiss Axio Imager.Z2 microscope (Zeiss) with 171 
AxioVision Release 4.8.2 software (Zeiss). 172 
2.8. Statistics 173 
All statistical analyses were performed using GraphPad Prism 5 Software (GraphPad Software Inc., 174 






3. Results 177 
3.1. PTPN2 controls the expression of PTPN1, PTPN9 and PTPN23 in HT-29 cells. 178 
We first investigated whether loss of PTPN2 in IECs might affect the expression of other tyrosine 179 
phosphatases with similar targets to PTPN2 or with reported functions in intestinal inflammation, 180 
namely PTPN1 (also known as PTP1B), PTPN9, PTPN11, PTPN22 and PTPN23. To examine 181 
whether their mRNA expression is altered upon deletion of PTPN2 in an IEC line, we treated HT-29 182 
colon carcinoma cells with PTPN2-specific small interfering (si) RNA or non-targeting control siRNA 183 
constructs. Cells were then treated with 100μg/ml IFN-y or 100 μg/ml TNF for 24 h. As expected, 184 
mRNA expression of PTPN2 was clearly reduced upon PTPN2-siRNA transfection showing that only 185 
40-50% of the initial PTPN2 mRNA expression was still retained (figure 1A). 186 
 187 
We found that TNF-, but not IFN-y-treatment slightly enhanced the expression of PTPN1 mRNA 188 
(figure 1B), while loss of PTPN2 resulted in lower basal PTPN1 mRNA expression, and its induction 189 
was significantly decreased upon TNF-treatment when compared to PTPN2 competent cells (p < 0.05). 190 
Of note, without treatment, PTPN9 mRNA expression was slightly, but significantly enhanced upon 191 
knockdown of PTPN2 (p < 0.01, figure 1C). TNF-treatment resulted in significantly reduced mRNA 192 
expression of PTPN9 in PTPN2-competent, as well as in PTPN2-knockdown cells compared to their 193 
respective controls. PTPN2 knockdown resulted in higher PTPN9 mRNA expression already in 194 
untreated controls as well as in response to treatment with TNF. PTPN11 mRNA expression was 195 
elevated in untreated PTPN2-knockdown cells when compared to untreated PTPN2-competent cells 196 
and TNF stimulation even further enhanced PTPN11 levels (p < 0.001, figure 1D), while IFN-y 197 
decreased PTPN11 mRNA levels in PTPN2-deficient cells. Further, IFN-y-treatment promoted 198 
PTPN22 mRNA expression in PTPN2-deficient IECs (p < 0.05, figure 1 E), whereas PTPN22 mRNA 199 
expression was not affected by TNF-stimulation (p < 0.001). 200 
 201 
Of note, basal levels of PTPN23 mRNA were significantly higher in PTPN2-knockdown cells when 202 
compared to PTPN2 competent HT-29 cells. This effect was clearly enhanced upon TNF-treatment (p 203 
< 0.001, figure 1F). TNF also induced PTPN23 mRNA levels in PTPN2 competent cells. Up-regulation 204 
of HD-PTP (the protein product of PTPN23) was confirmed by Western blotting, where we also found 205 





basal levels of HD-PTP in PTPN2-deficient cells. Of note the TNF-induced increase of HD-PTP was 207 
further potentiated in PTPN2-deficient cells, confirming our findings on mRNA level (figure 1G).  208 
 209 
  210 
3.2. PTPN2 regulates the expression of pro-inflammatory cytokines in HT29 cells. 211 
Having demonstrated that PTPN2 is involved in the regulation of the expression of mainly PTPN11 212 
and PTPN23 in HT29 IEC, we next analyzed the mRNA expression of pro-inflammatory cytokines. 213 
TNF stimulated IL-1b expression in both, PTPN2-competent and PTPN2-siRNA treated HT29 cells, 214 
but this effect was clearly less pronounced in PTPN2-siRNA transfected cells (p < 0.001, figure 2A). 215 
IL-18 mRNA expression on the other hand, was also upregulated upon TNF-stimulation in HT29 cells, 216 
and this effect was further enhanced in PTPN2-siRNA treated cells (p < 0.001, figure 2B). Even 217 
without treatment, PTPN2-deficient cells showed highly increased IL-18 mRNA expression which was 218 
clearly reduced in response to IFN-y-stimulation (p < 0.01). Increased IL-18 levels were also confirmed 219 
in Western blot analyses (Figure 2C) and IL-18 ELISA (Figure 2D). 220 
In addition, TNF stimulation resulted in highly increased mRNA expression of IL-8 mRNA in both, 221 
PTPN2-deficient and control cells (figure 2E). However, and in line with previous reports, PTPN2-222 
deficient cells expressed less IL-8 mRNA in response to TNF when compared to control cells (p < 223 
0.001). Since IFN-y-treatment had little or no effect in the so far analyzed genes, we confirmed 224 
response to IFN-y via analysis of mRNA levels of intercellular adhesion molecule-1 (ICAM-1). ICAM-1 225 
mRNA levels were highly increased upon IFN-y-stimulation in PTPN2-competent and even more in 226 
PTPN2-deficient IECs (p < 0.001, figure 2F). This was also true for TNF stimulation (p < 0.001).  227 
 228 
3.3. PTPN23 mRNA expression is increased in colon lysates from DSS-treated PTPN2xVilCre 229 
mice 230 
To further address the hypothesis that loss of PTPN2 might be compensated by altered expression of 231 
other tyrosine phosphatases, we next measured mRNA expression of Ptpn2, Ptpn1, Ptpn9, Ptpn11, 232 
Ptpn22, and Ptpn23 in colon tissue samples of wildtype (wt) mice and mice lacking PTPN2 specifically 233 
in intestinal epithelial cells (PTPN2xVilCre mice). The mice had either been left untreated or treated 234 





colitis[17]. As already described in Kasper et al this treatment resulted in similar intestinal inflammation 236 
in wt and PTPN2-VilCre mice [17]. 237 
 238 
As depicted in figure 3, mRNA expression of Ptpn2 was significantly reduced in colon pieces from 239 
PTPN2xVilCre mice, and loss of PTPN2 also resulted in a marked reduction of Ptpn1 mRNA levels 240 
(figure 3A+B). On the other hand, we did not observe any significant changes in Ptpn9 and Ptpn11 241 
mRNA expression in PTPN2xVilCre mice when compared to wt animals (figure 3C+D). Whereas DSS-242 
treated wt animals showed slightly enhanced Ptpn22 mRNA expression when compared to their 243 
control littermates without DSS, its expression was significantly decreased in PTPN2xVilCre mice that 244 
were treated with DSS (p < 0.01, figure 3E).  245 
Of note, while Ptpn23 mRNA was not altered in PTPN2xVilCre mice without induction of colitis, there 246 
was a clearly up-regulation of Ptpn23 upon DSS treatment in PTPN2-xVilCre mice (p < 0.01, figure 247 
3F). Up- regulation of PTPN23 in PTPN2-VilCre mice was further confirmed in immunohistochemical 248 
(IHC) staining of distal colon sections (Figure 3G). 249 
We have previously shown that loss of PTPN2 promotes activation of inflammasomes [18], and 250 
subsequent secretion of IL-1β and IL-18. Therefore, we also addressed whether loss of PTPN2 in 251 
epithelial cells affects expression of Il1b and Il18 mRNA. While Il1b mRNA expression level was not 252 
altered in all four groups, Il18 mRNA expression showed a trend towards a reduction in DSS treated 253 
wt and PTPN2xVilCre mice compared to their corresponding controls (figure 3H+I), possibly due to a 254 
negative feedback regulation. This hypothesis was confirmed by addressing IL-18 levels in serum by 255 
ELISA, where we found increased IL-18 protein levels in DSS treated WT mice when compared to 256 
water controls. Of note, this increase was further enhanced in DSS-treated PTPN2-VilCre mice 257 
(Figure 3J). This is in line with our previous finding that the regulation of IL-1 and IL-18 via PTPN2 is 258 
mediated via changes in protein activation, and not via changes in mRNA levels [18]. 259 
 260 
3.4. mRNA expression level in colon lysates from AOM-DSS treated PTPN2xVilCre mice 261 
In a next step, we aimed to address whether loss of PTPN2 also affects expression of other 262 
phosphatases in a model of colitis-associated tumour formation. For this aim, wt mice and 263 
PTPN2xVilCre littermates were subjected to a commonly used mouse model for colorectal carcinoma, 264 





and tumor development as previously described in Spalinger et al [18]. In this experiment, colon tissue 266 
pieces from non-tumour tissue and from tumour tissue have been collected for mRNA analysis and we 267 
here investigated the expression levels of Ptpn2, Ptpn1, Ptpn9, Ptpn11, Ptpn22, Ptpn23, Il1b and Il18 268 
mRNA. 269 
 270 
Ptpn2 mRNA expression was decreased in PTPN2xVilCre mice, but not affected by DSS/AOM 271 
treatment in tumour or non-tumour tissue (figure 4A). As shown in figure 4B, Ptpn1 mRNA expression 272 
tended to be higher in non-tumour tissue from mice treated with AOM/DSS than in control littermates, 273 
although this effect was not statistically significant. Regardless of the genotype, there was significantly 274 
more Ptpn1 expressed in tumour tissue than in colon tissue from healthy wt mice (p < 0.01, figure 4B) 275 
– this was in contrast to our findings obtained using acute DSS colitis model, where Ptpn1 expression 276 
was markedly decreased upon deletion of PTPN2. In contrast to our cell culture experiment, but in line 277 
with results from the DSS acute colitis, Ptpn9 expression was not affected by AOM/DSS treatment and 278 
did not show an altered mRNA expression profile. Likewise, Ptpn11 mRNA levels were not affected by 279 
treatment or genotype (figure 4C+D).  280 
 281 
Ptpn22 mRNA expression was increased in non-tumour colon tissue from AOM/DSS treated 282 
PTPN2xVilCre mice compared to healthy PTPN2xVilCre (p < 0.05) and wt control mice (p < 0.01, 283 
figure 4E). Upon AOM/DSS treatment, Ptpn22 expression was significantly decreased in tumour tissue 284 
from wt mice, when compared to non-tumour tissue from the same mice (p < 0.05, figure 4E). 285 
Although there seems also to be a decrease of Ptpn22 expression in tumour tissue from 286 
PTPN2xVilCre mice, this reduction was far less pronounced, and tumour tissue from PTPN2xVilCre 287 
mice tended to express more Ptpn22 than wt tumour tissue (figure 4E).  288 
 289 
In the colon tumour mouse model, we observed that Ptpn23 mRNA expression was clearly increased 290 
in colonic non-tumour tissue derived from PTPN2xVilinCre mice after AOM/DSS treatment compared 291 
to wt control mice (p < 0.01, figure 4F) and wt mice treated with AOM/DSS (p < 0.05). Interestingly, 292 
Ptpn23 mRNA expression was not altered in tumour tissue of neither PTPN2 wt nor PTPN2xVilCre 293 
mice when compared to the respective untreated control mice. mRNA expression data was then 294 
confirmed by IHC, where we found increased HD-PTP expression in PTPN2-VilCre mice in general, 295 






When analyzing the expression of Il1b and Il18, we observed that in general, Il1b mRNA was 298 
upregulated upon AOM/DSS treatment (figure 6A+B). The strongest increase in expression was found 299 
in tumour tissue of wt mice, followed by tumour tissue of PTPN2-VilCre mice. In contrast to Il1b, Il18 300 
mRNA expression was reduced in wt mice treated with AOM/DSS (p < 0.01) and in tumour tissue from 301 
wt (p < 0.01) and PTPN2xVilCre mice (p < 0.05). Surprisingly, Il18 mRNA expression was highest in 302 
wt control mice when compared to all other groups, which, again might result from a negative 303 
feedback regulation. This hypothesis was confirmed using ELISA for IL-18, where we found a clear 304 






4. Discussion 307 
In this study, we investigated how loss of PTPN2 in IECs modulates the expression of related tyrosine 308 
phosphatases in HT-29 cells, colon lysates and tumour tissue of PTPN2xVilCre mice. Our results 309 
showed that in vivo, loss of PTPN2 in intestinal epithelial cells mainly affected the expression of 310 
Ptpn23 mRNA, while Ptpn9 and Ptpn11 were not changed in a consistent manner among the different 311 
experimental settings. This was supported by our HT29 cell line studies, where we identified as a most 312 
striking finding a regulatory loop between PTPN2 and PTPN23 in IECs (Figure 7). 313 
 314 
In the in vivo setting we found that among the studied tyrosine phosphatases, only PTPN23 was more 315 
expressed in tissue of PTPN2xVilCre mice compared to their wt littermates. This result is consistent 316 
with our finding in the in vitro experiments, where PTPN23 mRNA expression was also increased in all 317 
three groups of HT29-PTPN2-knockdown cells compared to the respective control groups. It has been 318 
shown that PTPN23 is essential during embryonic development and its expression in adult mice is 319 
limited to the epithelium of multiple organs including the epithelium of the stomach, small intestine and 320 
colon [20]. PTPN23 encodes for the protein HD-PTP, which controls cell migration and endocytosis 321 
[21]. The role of PTPN23 in IECs in the intestine has not been studied yet. However, our recent 322 
unpublished findings indicate that PTPN23/HD-PTP might control proliferation and migration of IECs.  323 
Interestingly, PTPN23 expression was only increased in non-tumour tissue from PTPN2xVilCre mice 324 
treated with AOM/DSS but not in the tumour tissue itself. This indicates that in the course of tumour 325 
formation and progression, PTPN23 upregulation seems to be lost and therefore also its 326 
compensatory function. This is in line with several studies that show that loss of PTPN23 promotes the 327 
development of breast cancer and that hemizygous loss of PTPN23 facilitates spontaneous 328 
tumourgenesis [22,23].  329 
 330 
A very interesting observation is that in PTPN2-deficient cells, the mRNA expression pattern of IL-18 331 
follows the expression pattern of PTPN23. This is in contrast to Il1b mRNA levels. Those findings 332 
suggest that in absence of PTPN2, PTPN23 might play a critical role for the regulation of IL-18 333 
expression and it might be interesting to investigate whether PTPN23 might be involved in the 334 
regulation of IL-18 protein expression and activation as well. 335 





In addition to PTPN23 upregulation, PTPN22 mRNA expression was reduced in PTPN2xVilCre mice 337 
upon DSS treatment. We have previously shown that PTPN22 is reduced in the intestine of IBD 338 
patients and that it plays a protective role during intestinal inflammation [24]. Further, PTPN22 339 
deficient mice are more affected by DSS-induced colitis [25-27]. One possible explanation for reduced 340 
PTPN22 expression might be the fact that TNF and IL-1β supress PTPN22 expression [28]. The 341 
findings that PTPN22 was clearly reduced in the tumour tissue compared to the non-tumour tissue in 342 
wild-type and PTPN2xVilCre mice suggests that PTPN22 might also exert somehow a tumour 343 
suppressor function in the colon regardless of PTPN2. 344 
 345 
Of note, we found reduced PTPN1 mRNA expression in PTPN2xVilCre mice in the acute DSS 346 
experiment, regardless whether the mice were treated with DSS or not, while this was not the case in 347 
the AOM-DSS experiment. This seems contradictory at first, but might be explained by the fact that 348 
the mice are several weeks older at the end of the AOM-DSS tumour induction. We showed that in 349 
vitro, PTPN1 expression is clearly regulated upon presence of inflammatory cytokines. Low grade 350 
inflammatory processes might therefore account for a lack of genotype-specific differences in older 351 
mice. PTPN1 is closely related to PTPN2, sharing approximately 70% of their catalytic domain 352 
sequence [29]. Since PTPN1 is a negative regulator of JAK/STAT-mediated signalling regulating 353 
myeloid-derived suppressor cells, PTPN1 null mice are more resistant to DSS-induced colitis due to 354 
expansion of protecting myeloid-derived suppressor cells that modulate cytokine secretion [30]. 355 
Therefore, the marked reduction of PTPN1 in our acute experiments might also contribute to the fact 356 
that PTPN2xVilCre mice do not suffer from pronounced acute colitis. 357 
 358 
We observed that PTPN9 mRNA was highest in untreated PTPN2-deficient HT-29 cells. Its expression 359 
decreased strongly upon stimulation with the pro-inflammatory cytokines IFN-y and TNF. However, the 360 
expression of PTPN9 mRNA was not changed in PTPN2xVilCre mice during induction of colitis, and it 361 
is well possible that other inflammatory cytokines, such as IL-6 or IL-1 might counteract the effects of 362 
TNF/IFN-y in the in vivo situation. Hence, further studies would be necessary to fully understand the 363 
regulation of PTPN9 in the (inflamed) intestine. 364 
 365 
Interestingly, we found increased expression of PTPN11 in PTPN2-deficient HT29 cells upon TNF-366 





on IFN-y-induced signalling cascades [31]. Several studies proposed that PTPN11 is a protective 368 
factor against gut inflammation [28,32] and its upregulation in IECs might represent a compensatory 369 
effect for the loss of PTPN2. Nevertheless, we did not observe significant differences in PTPN11 370 
mRNA expression in colon lysates from PTPN2xVilCre mice upon colitis induction, leading to the 371 
conclusion that this phosphatase might play a subordinate role to compensate for the loss of PTPN2 in 372 
vivo. Further, in the in vivo situation, only IEC lack PTPN2, while all other cells express normal PTPN2 373 
levels. In our study, we measured RNA in whole colon tissue, which includes IEC, as well as myeloid 374 
and lymphoid immune cells. Although our results show that many of the in vitro effects are mirrored in 375 
the whole-tissue studies, the effect on PTPN11 expression observed in the samples from the in vivo 376 
experiment might reflect the effects resulting from non-IEC cells. Given the complex interaction 377 
between phosphatases and various intracellular signalling molecules, network analyses might be an 378 
interesting further direction to more completely understand how loss of PTPN2 in IEC affects cellular 379 
signalling pathways as a whole, as well as possible interaction between different cell types present in 380 
the intestine. 381 
 382 
It should be considered that in our cell culture experiment, knockdown of PTPN2 was not complete, 383 
hence the effects in the in vitro experiments might be less pronounced than from a complete knockout, 384 
and might more closely reflect the situation observed in patients where presence of the variants 385 
results in reduced PTPN2 function but not its complete loss. 386 
 387 
Taken together, our results demonstrate that depletion of PTPN2 in intestinal epithelial cells affects 388 
the expression of other tyrosine phosphatases, which might contribute to the fact that mice lacking 389 
PTPN2 specifically in IECs do not develop pronounced colitis. Most strikingly, there was a marked, 390 
and consistent upregulation of PTPN23 in PTPN2 deficient cells and in colon tissue from 391 
PTPN2xVilCre mice, indicating that in vivo, this phosphatase might be the most relevant to 392 
compensate for the lack of PTPN2.  393 





5. References 395 
 396 
1 Beaugerie L, Itzkowitz SH: Cancers Complicating Inflammatory Bowel Disease. 397 
N Engl J Med 2015;373:195. 398 
2 Axelrad JE, Lichtiger S, Yajnik V: Inflammatory bowel disease and cancer: The 399 
role of inflammation, immunosuppression, and cancer treatment. World J 400 
Gastroenterol 2016;22:4794-4801. 401 
3 Zhang YZ, Li YY: Inflammatory bowel disease: pathogenesis. World J 402 
Gastroenterol 2014;20:91-99. 403 
4 Peters LA, Perrigoue J, Mortha A, Iuga A, Song WM, Neiman EM, Llewellyn 404 
SR, Di Narzo A, Kidd BA, Telesco SE, Zhao Y, Stojmirovic A, Sendecki J, Shameer 405 
K, Miotto R, Losic B, Shah H, Lee E, Wang M, Faith JJ, Kasarskis A, Brodmerkel C, 406 
Curran M, Das A, Friedman JR, Fukui Y, Humphrey MB, Iritani BM, Sibinga N, 407 
Tarrant TK, Argmann C, Hao K, Roussos P, Zhu J, Zhang B, Dobrin R, Mayer LF, 408 
Schadt EE: A functional genomics predictive network model identifies regulators of 409 
inflammatory bowel disease. Nat Genet 2017;49:1437-1449. 410 
5 Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, 411 
Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, 412 
Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, 413 
Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, 414 
Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, 415 
Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel JF, Cottone M, 416 
Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, 417 
Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, 418 
Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, 419 
Libioulle C, Louis E, Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro 420 
M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers 421 
PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, 422 
D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, 423 
Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson 424 
H, Daly MJ, Parkes M: Genome-wide meta-analysis increases to 71 the number of 425 
confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125. 426 
6 de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, 427 
Rice DL, Gutierrez-Achury J, Ji SG, Heap G, Nimmo ER, Edwards C, Henderson P, 428 
Mowat C, Sanderson J, Satsangi J, Simmons A, Wilson DC, Tremelling M, Hart A, 429 
Mathew CG, Newman WG, Parkes M, Lees CW, Uhlig H, Hawkey C, Prescott NJ, 430 
Ahmad T, Mansfield JC, Anderson CA, Barrett JC: Genome-wide association study 431 
implicates immune activation of multiple integrin genes in inflammatory bowel 432 
disease. Nat Genet 2017;49:256-261. 433 
7 Lees CW, Barrett JC, Parkes M, Satsangi J: New IBD genetics: common 434 
pathways with other diseases. Gut 2011;60:1739-1753. 435 
8 Lee H, Yi JS, Lawan A, Min K, Bennett AM: Mining the function of protein 436 
tyrosine phosphatases in health and disease. Semin Cell Dev Biol 2015;37:66-72. 437 
9 Bussières-Marmen S, Hutchins AP, Schirbel A, Rebert N, Tiganis T, Fiocchi C, 438 
Miranda-Saavedra D, Tremblay ML: Characterization of PTPN2 and its use as a 439 
biomarker. Methods 2014;65:239-246. 440 
10 You-Ten KE, Muise ES, Itié A, Michaliszyn E, Wagner J, Jothy S, Lapp WS, 441 
Tremblay ML: Impaired bone marrow microenvironment and immune function in T 442 





11 Khor B, Gardet A, Xavier RJ: Genetics and pathogenesis of inflammatory 444 
bowel disease. Nature 2011;474:307-317. 445 
12 Michielan A, D'Incà R: Intestinal Permeability in Inflammatory Bowel Disease: 446 
Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. Mediators Inflamm 447 
2015;2015:628157. 448 
13 Coskun M: Intestinal epithelium in inflammatory bowel disease. Front Med 449 
(Lausanne) 2014;1:24. 450 
14 Beaurepaire C, Smyth D, McKay DM: Interferon-gamma regulation of intestinal 451 
epithelial permeability. J Interferon Cytokine Res 2009;29:133-144. 452 
15 Scharl M, Paul G, Weber A, Jung BC, Docherty MJ, Hausmann M, Rogler G, 453 
Barrett KE, McCole DF: Protection of epithelial barrier function by the Crohn's 454 
disease associated gene protein tyrosine phosphatase n2. Gastroenterology 455 
2009;137:2030-2040 e2035. 456 
16 Scharl M, McCole DF, Weber A, Vavricka SR, Frei P, Kellermeier S, Pesch T, 457 
Fried M, Rogler G: Protein tyrosine phosphatase N2 regulates TNFα-induced 458 
signalling and cytokine secretion in human intestinal epithelial cells. Gut 459 
2011;60:189-197. 460 
17 Kasper SH, Spalinger MR, Leonardi I, Gerstgrasser A, Raselli T, Gottier C, 461 
Atrott K, Frey-Wagner I, Fischbeck-Terhalle A, Rogler G, Scharl M: Deficiency of 462 
Protein Tyrosine Phosphatase Non-Receptor Type 2 in Intestinal Epithelial Cells Has 463 
No Appreciable Impact on Dextran Sulphate Sodium Colitis Severity But Promotes 464 
Wound Healing. Digestion 2016;93:249-259. 465 
18 Spalinger MR, Manzini R, Hering L, Riggs JB, Gottier C, Lang S, Atrott K, 466 
Fettelschoss A, Olomski F, Kundig TM, Fried M, McCole DF, Rogler G, Scharl M: 467 
PTPN2 Regulates Inflammasome Activation and Controls Onset of Intestinal 468 
Inflammation and Colon Cancer. Cell Rep 2018;22:1835-1848. 469 
19 Parang B, Barrett CW, Williams CS: AOM/DSS Model of Colitis-Associated 470 
Cancer. Methods Mol Biol 2016;1422:297-307. 471 
20 Gingras MC, Kharitidi D, Chénard V, Uetani N, Bouchard M, Tremblay ML, 472 
Pause A: Expression analysis and essential role of the putative tyrosine phosphatase 473 
His-domain-containing protein tyrosine phosphatase (HD-PTP). Int J Dev Biol 474 
2009;53:1069-1074. 475 
21 Gahloth D, Heaven G, Jowitt TA, Mould AP, Bella J, Baldock C, Woodman P, 476 
Tabernero L: The open architecture of HD-PTP phosphatase provides new insights 477 
into the mechanism of regulation of ESCRT function. Sci Rep 2017;7:9151. 478 
22 Zhang S, Fan G, Hao Y, Hammell M, Wilkinson JE, Tonks NK: Suppression of 479 
protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation 480 
of FYN kinase. Genes Dev 2017;31:1939-1957. 481 
23 Manteghi S, Gingras MC, Kharitidi D, Galarneau L, Marques M, Yan M, Cencic 482 
R, Robert F, Paquet M, Witcher M, Pelletier J, Pause A: Haploinsufficiency of the 483 
ESCRT Component HD-PTP Predisposes to Cancer. Cell Rep 2016;15:1893-1900. 484 
24 Spalinger MR, Lang S, Vavricka SR, Fried M, Rogler G, Scharl M: Protein 485 
tyrosine phosphatase non-receptor type 22 modulates NOD2-induced cytokine 486 
release and autophagy. PLoS One 2013;8:e72384. 487 
25 Chang HH, Miaw SC, Tseng W, Sun YW, Liu CC, Tsao HW, Ho IC: PTPN22 488 
modulates macrophage polarization and susceptibility to dextran sulfate sodium-489 
induced colitis. J Immunol 2013;191:2134-2143. 490 
26 Spalinger MR, Kasper S, Gottier C, Lang S, Atrott K, Vavricka SR, Scharl S, 491 
Raselli T, Frey-Wagner I, Gutte PM, Grutter MG, Beer HD, Contassot E, Chan AC, 492 





tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J 494 
Clin Invest 2016;126:4388. 495 
27 Wang Y, Shaked I, Stanford SM, Zhou W, Curtsinger JM, Mikulski Z, Shaheen 496 
ZR, Cheng G, Sawatzke K, Campbell AM, Auger JL, Bilgic H, Shoyama FM, 497 
Schmeling DO, Balfour HH, Hasegawa K, Chan AC, Corbett JA, Binstadt BA, 498 
Mescher MF, Ley K, Bottini N, Peterson EJ: The autoimmunity-associated gene 499 
PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity. 500 
Immunity 2013;39:111-122. 501 
28 Spalinger MR, Scharl M: The role for protein tyrosine phosphatase non-502 
receptor type 22 in regulating intestinal homeostasis. United European Gastroenterol 503 
J 2016;4:325-332. 504 
29 Asante-Appiah E, Ball K, Bateman K, Skorey K, Friesen R, Desponts C, 505 
Payette P, Bayly C, Zamboni R, Scapin G, Ramachandran C, Kennedy BP: The YRD 506 
motif is a major determinant of substrate and inhibitor specificity in T-cell protein-507 
tyrosine phosphatase. J Biol Chem 2001;276:26036-26043. 508 
30 Zhang J, Wang B, Zhang W, Wei Y, Bian Z, Zhang CY, Li L, Zen K: Protein 509 
tyrosine phosphatase 1B deficiency ameliorates murine experimental colitis via the 510 
expansion of myeloid-derived suppressor cells. PLoS One 2013;8:e70828. 511 
31 McCole DF: Regulation of epithelial barrier function by the inflammatory bowel 512 
disease candidate gene, PTPN2. Ann N Y Acad Sci 2012;1257:108-114. 513 
32 Coulombe G, Rivard N: New and Unexpected Biological Functions for the Src-514 
Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract. 515 
Cell Mol Gastroenterol Hepatol 2016;2:11-21. 516 
 517 





6. Figure Legends 519 
Figure 1. Deletion of PTPN2 in HT-29 cells results in enhanced PTPN9, PTPN11 and PTPN23 520 
expression. 521 
HT-29 cells were treated with non-targeting control siRNA or with PTPN2-specific siRNA and activated 522 
with 100 ng/ml IFN-y or 100 ul/ml TNF for 24h as indicated. Cell lysates were analysed for mRNA 523 
expression of A) PTPN2, B) PTPN1, C) PTPN9, D) PTPN11, E) PTPN22, and F) PTPN23. Data were 524 
normalized to cells treated with control siRNA without activation. Asterisks denote significant 525 
differences * p < 0.05, ** p < 0.01, *** p < 0.001 Newman Keul’s test; Ctr, Control; Actb, actin beta. 526 
 527 
Figure 2. Deletion of PTPN2 in HT-29 cells affects mRNA expression of pro-inflammatory 528 
cytokines. HT-29 cells were treated with non-targeting siRNA or with PTPN2-specific siRNA and 529 
activated with 100 ng/ml IFN-y or 100 ul/ml TNF for 24h as indicated. Cell lysates were analysed for 530 
mRNA expression of A) IL1B, and B) IL18. C) Protein levels of IL-18 were analysed by Western blot 531 
and ELISA. mRNA levels  of E) IL8, and F) ICAM1 were analysed by qPCR. Data were normalized to 532 
cells treated with control siRNA without activation. Asterisks denote significant differences * p < 0.05, 533 
** p < 0.01, *** p < 0.001 Newman Keul’s test; Ctr, Control; Actb, actin beta. 534 
 535 
Figure 3. Colon lysates from DSS-treated PTPN2xVilCre mice show increased expression of 536 
PTPN23. 537 
C57/Bl6 mice with a floxed Ptpn2 gene (wt) and PTPN2fl/fl mice expressing Cre-recombinase under 538 
the Villin promoter that lack Ptpn2 specifically in intestinal epithelial cells (PTPN2xVilCre mice) were 539 
treated with water or 2% DSS. Colon lysates of PTPN2xVilCre mice were analysed for mRNA 540 
expression of A) Ptpn2, B) Ptpn1, C) Ptpn9, D) Ptpn11, E) Ptpn22, and F) Ptpn23 by RT-PCR. Data 541 
were normalized to Actb. G) Paraffin-embedded tissue from the terminal colon was stained for HD-542 
PTP (brown), the protein product of PTPN23. mRNA expression of H) IL-1b and I) IL18 were analysed 543 
by RT-qPCR, and J) serum IL-18 levels detected by ELISA. Each symbol stands for one individual 544 
mouse and horizontal bars indicate the mean. Asterisks denote significant differences * p < 0.05, ** p 545 
< 0.01, *** p < 0.001 Newman Keul’s test; wt, wildtype; DSS, dextran sulphate sodium; Actb, actin 546 






Figure 4. PTPN23 expression is enhanced in PTPN2xVilCre mice after AOM/DSS treatment but 549 
not increased in tumour tissue.  550 
To induce colitis-associated tumours, PTPN2xVilCre mice were treated for 3 consecutive cycles 551 
consisting of 7 days with 1.5% DSS followed by 10 days recovery phase, each. At the first day of each 552 
cycle, 10mg/kg body weight Azoxymethane (AOM) was injected. Colon lysates and tumour pieces 553 
were analysed for mRNA expression of A) PTPN2, B) PTPN1, C) PTPN9, D) PTPN11, E) PTPN22, 554 
and F) PTPN23 by RT-PCR. Data were normalized to Actb. Asterisks denote significant differences * 555 
p < 0.05, ** p < 0.01, *** p < 0.001 Newman Keul’s test; wt, wildtype; ko, knockout; AOM, 556 
azoxymethane; AOM T, azoxymethane treated group, tumour tissue. 557 
 558 
Figure 5. PTPN23 protein expression is enhanced in PTPN2xVilCre mice after AOM/DSS 559 
treatment.  560 
To induce colitis-associated tumours, PTPN2xVilCre mice were treated for 3 consecutive cycles 561 
consisting of 7 days with 1.5% DSS followed by 10 days recovery phase, each. At the first day of each 562 
cycle, 10mg/kg body weight Azoxymethane (AOM) was injected. Paraffin-embedded tissue from the 563 
terminal colon was stained for HD-PTP (brown), the protein product of PTPN23. 564 
  565 
Figure 6. Altered expression of inflammatory cytokines in PTPN2xVilCre mice after AOM/DSS 566 
treatment. Mice were treated as in Figure 4 and colon lysates and tumour pieces analysed for A) IL-567 
1b and B) IL-18 mRNA expression. Data were normalized to Actb. Asterisks denote significant 568 
differences * p < 0.05, ** p < 0.01, *** p < 0.001 Newman Keul’s test; wt, wildtype; ko, knockout; AOM, 569 
azoxymethane; AOM T, azoxymethane treated group, tumour tissue. 570 
 571 
Figure 7. Proposed mechanism how PTPN23 might counteracts the effect of PTPN2 deficiency. 572 
Deletion of PTPN2 promotes pro-inflammatory and pro-oncogenic signalling cascades, such as 573 
JAK/STAT signalling, EGFR signalling and IL-18 secretion. At the same time, it promotes the 574 
expression of PTPN23. PTPN23 in turn inhibits EGFR signalling and IL-18 induced effects, thus 575 
counteracting the effects of PTPN2 deficiency. Blue arrows: enhanced expression, red arrows with 576 
blunt ends: suppression. Dashed lines: proposed effects, solid lines: effects supported by literature.  577 
 578 
